Michael T. Lotze

81.9k total citations · 27 hit papers
504 papers, 57.5k citations indexed

About

Michael T. Lotze is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Michael T. Lotze has authored 504 papers receiving a total of 57.5k indexed citations (citations by other indexed papers that have themselves been cited), including 280 papers in Immunology, 189 papers in Oncology and 151 papers in Molecular Biology. Recurrent topics in Michael T. Lotze's work include Immunotherapy and Immune Responses (153 papers), Immune Cell Function and Interaction (100 papers) and Cancer Immunotherapy and Biomarkers (74 papers). Michael T. Lotze is often cited by papers focused on Immunotherapy and Immune Responses (153 papers), Immune Cell Function and Interaction (100 papers) and Cancer Immunotherapy and Biomarkers (74 papers). Michael T. Lotze collaborates with scholars based in United States, China and Germany. Michael T. Lotze's co-authors include Daolin Tang, Herbert J. Zeh, Rui Kang, Steven A. Rosenberg, Kevin J. Tracey, Herbert J. Zeh, Claudia A. Seipp, Timothy R. Billiar, Walter J. Storkus and R Kang and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and JAMA.

In The Last Decade

Michael T. Lotze

498 papers receiving 56.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone

1987 2.2k citations Michael T. Lotze et al. profile →
High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal

2005 2.1k citations Michael T. Lotze et al. profile →
Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer

1985 2.0k citations Michael T. Lotze et al. profile →
The Beclin 1 network regulates autophagy and apoptosis

2011 2.0k citations Herbert J. Zeh, Michael T. Lotze et al. profile →
Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma

1988 1.8k citations Michael T. Lotze et al. profile →
Autophagy promotes ferroptosis by degradation of ferritin

2016 1.8k citations Michael T. Lotze, Herbert J. Zeh et al. profile →
High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993

1999 1.5k citations Michael T. Lotze et al. profile →
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma

2008 1.3k citations Michael T. Lotze et al. profile →
The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion

2005 944 citations Allan Tsung, Michael T. Lotze et al. profile →
PAMPs and DAMPs: signal 0s that spur autophagy and immunity

2012 916 citations Daolin Tang, Rui Kang et al. profile →
Gene Transfer into Humans — Immunotherapy of Patients with Advanced Melanoma, Using Tumor-Infiltrating Lymphocytes Modified by Retroviral Gene Transduction

1990 898 citations Michael T. Lotze, James C. Yang et al. profile →
HMGB1 in health and disease

2014 787 citations Rui Kang, Herbert J. Zeh et al. profile →
Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients

1989 786 citations Michael T. Lotze et al. profile →
Endogenous HMGB1 regulates autophagy

2010 778 citations Daolin Tang, Rui Kang et al. profile →
The Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4 Activity

2017 737 citations Shan Zhu, Lin Zhang et al. profile →
Principles and Current Strategies for Targeting Autophagy for Cancer Treatment

2011 728 citations Ravi K. Amaravadi, Michael T. Lotze et al. Clinical Cancer Research profile →
Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.

1996 717 citations Michael T. Lotze et al. profile →
AMPK-Mediated BECN1 Phosphorylation Promotes Ferroptosis by Directly Blocking System Xc– Activity

2018 581 citations Michael T. Lotze, Herbert J. Zeh et al. profile →
Inflammation and necrosis promote tumour growth

2004 550 citations Michael T. Lotze et al. profile →
RAGE (Receptor for Advanced Glycation Endproducts), RAGE Ligands, and their role in Cancer and Inflammation

2009 504 citations Rui Kang, Daolin Tang et al. profile →
In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

1985 488 citations Michael T. Lotze et al. profile →
High-mobility group box 1 and cancer

2010 447 citations Daolin Tang, Rui Kang et al. profile →
HSPA5 Regulates Ferroptotic Cell Death in Cancer Cells

2017 447 citations Shan Zhu, Qiuhong Zhang et al. Cancer Research profile →
Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.

1981 425 citations Michael T. Lotze et al. PubMed profile →
Clockophagy is a novel selective autophagy process favoring ferroptosis

2019 392 citations Shan Zhu, Michael T. Lotze et al. profile →
The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents

2015 390 citations Michael T. Lotze, Herbert J. Zeh et al. profile →
The multifunctional protein HMGB1: 50 years of discovery

2023 198 citations Daolin Tang, Rui Kang et al. profile →

Peers

Countries citing papers authored by Michael T. Lotze

Since Specialization

Citations

This map shows the geographic impact of Michael T. Lotze's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael T. Lotze with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael T. Lotze more than expected).

Fields of papers citing papers by Michael T. Lotze

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael T. Lotze. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael T. Lotze. The network helps show where Michael T. Lotze may publish in the future.

Co-authorship network of co-authors of Michael T. Lotze

This figure shows the co-authorship network connecting the top 25 collaborators of Michael T. Lotze. A scholar is included among the top collaborators of Michael T. Lotze based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael T. Lotze. Michael T. Lotze is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee 2025 ·Journal for ImmunoTherapy of Cancer ·George Coukos, Marco Donia, Brian Gastman, Stephanie L. Goff, Alena Gros, Alexandre Harari, (unknown), Fumito Ito, Ajay V. Maker, John E. Mullinax, (unknown), Sara I. Pai, Sangeetha Prabhakaran, (unknown), Natalie L. Silver, Paula Marincola Smith, Simon Turcotte, (unknown), James C. Yang, Michael T. Lotze	0
2	Rapamycin mitigates inflammation‐mediated disc matrix homeostatic imbalance by inhibiting mTORC1 and inducing autophagy through Akt activation 2024 ·JOR Spine ·Takashi Yurube, William Buchser, Zhongying Zhang, Prashanta Silwal, Michael T. Lotze, James D. Kang, Gwendolyn Sowa, Nam V. Vo	13
3	Chloroquine reduces neutrophil extracellular trap (NET) formation through inhibition of peptidyl arginine deiminase 4 (PAD4) 2023 ·Clinical & Experimental Immunology ·(unknown), (unknown), Pranav Murthy, Michael T. Lotze, Herbert J. Zeh, Lori Hazlehurst, Werner J. Geldenhuys, Brian A. Boone	23
4	Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance 2023 ·Cancer Research ·Renzo Perales‐Linares, Nektaria Maria Leli, (unknown), Silvia Beghi, (unknown), (unknown), Andrea Giglio, (unknown), Mireia Uribe‐Herranz, (unknown), Stefano Pierini, Sergei Pustylnikov, Giorgos Skoufos, Yoseph Barash, Artemis G. Hatzigeorgiou, Constantinos Koumenis, Amit Maity, Michael T. Lotze, Andrea Facciabene	3
5	Sequestsome-1/p62-targeted small molecules for pancreatic cancer therapy 2021 ·Drug Discovery Today ·(unknown), Pranav Murthy, (unknown), Terence F. McGuire, Michael T. Lotze, Xiang‐Qun Xie	8
6	A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients 2020 ·Clinical Cancer Research ·Herbert J. Zeh, Nathan Bahary, Brian A. Boone, Aatur D. Singhi, Jennifer L. Miller-Ocuin, Daniel P. Normolle, Amer H. Zureikat, Melissa E. Hogg, David L. Bartlett, Kenneth K. Lee, Allan Tsung, J. Wallis Marsh, Pranav Murthy, Daolin Tang, Natalie Seiser, Ravi K. Amaravadi, Virginia Espina, Lance A. Liotta, Michael T. Lotze	170
7	Prolactin Promotes Fibrosis and Pancreatic Cancer Progression 2019 ·Cancer Research ·(unknown), Gina M. Coudriet, Angela Criscimanna, (unknown), (unknown), Aatur D. Singhi, Zobeida Cruz‐Monserrate, Peter J. Bailey, Michael T. Lotze, Herbert J. Zeh, Jing Hu, Vincent Goffin, George K. Gittes, Andrew V. Biankin, Farzad Esni	38
8	Making cold malignant pleural effusions hot: driving novel immunotherapies 2019 ·OncoImmunology ·Pranav Murthy, (unknown), (unknown), (unknown), Yue Wang, James D. Luketich, Adam C. Soloff, Rajeev Dhupar, Michael T. Lotze	57
9	DNA released from neutrophil extracellular traps (NETs) activates pancreatic stellate cells and enhances pancreatic tumor growth 2019 ·OncoImmunology ·Jennifer L. Miller-Ocuin, Xiaoyan Liang, Brian A. Boone, (unknown), Aatur D. Singhi, Daolin Tang, Rui Kang, Michael T. Lotze, Herbert J. Zeh	110
10	Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps 2018 ·BMC Cancer ·Brian A. Boone, Pranav Murthy, Jennifer L. Miller-Ocuin, (unknown), (unknown), Xiaoyan Liang, Mark A. Ross, Callen T. Wallace, Jason L. Sperry, Michael T. Lotze, Matthew D. Neal, Herbert J. Zeh	135
11	HSPA5 Regulates Ferroptotic Cell Death in Cancer Cells breakdown → 2017 ·Cancer Research ·Shan Zhu, Qiuhong Zhang, Xiaofan Sun, Herbert J. Zeh, Michael T. Lotze, Rui Kang, Daolin Tang	447
12	Bortezomib Treatment Sensitizes Oncolytic HSV-1–Treated Tumors to NK Cell Immunotherapy 2016 ·Clinical Cancer Research ·Ji Young Yoo, Alena Cristina Jaime‐Ramirez, Chelsea Bolyard, (unknown), (unknown), Jeffrey Wojton, Brian Hurwitz, Theresa Relation, Tae Jin Lee, Michael T. Lotze, (unknown), Jianying Zhang, Carlo M. Croce, Jianhua Yu, Michael A. Caligiuri, Matthew Old, Balveen Kaur	66
13	High-Mobility Group Box 1 Promotes Hepatocellular Carcinoma Progression through miR-21–Mediated Matrix Metalloproteinase Activity 2015 ·Cancer Research ·Man Chen, Yao Liu, Patrick R. Varley, Ying Chang, (unknown), Hai Huang, Daolin Tang, Michael T. Lotze, Ju‐Sheng Lin, Allan Tsung	78
14	Inhibiting Systemic Autophagy during Interleukin 2 Immunotherapy Promotes Long-term Tumor Regression 2012 ·Cancer Research ·Xiaoyan Liang, Michael E. de Vera, William Buchser, (unknown), Patricia Loughran, Donna B. Stolz, Per Basse, Tao Wang, Bennett Van Houten, Herbert J. Zeh, Michael T. Lotze	125
15	p53/HMGB1 Complexes Regulate Autophagy and Apoptosis 2012 ·Cancer Research ·Kristen M. Livesey, Rui Kang, Philip Vernon, William Buchser, Patricia Loughran, Simon C. Watkins, Lin Zhang, James J. Manfredi, Herbert J. Zeh, Luyuan Li, Michael T. Lotze, Daolin Tang	220
16	Cell-Mediated Autophagy Promotes Cancer Cell Survival 2012 ·Cancer Research ·William Buchser, Thomas Laskow, (unknown), Huimin Lin, Michael T. Lotze	115
17	Natural killer cells : basic science and clinical application 2010 ·Elsevier eBooks ·Michael T. Lotze, Angus W. Thomson	26
18	Dicer-regulated micro RNAs 222 and 339 promote immune-escape of cancer cells through downregulation of ICAM-1 2008 ·Cancer Research ·Ryo Ueda, Gary Kohanbash, Kotaro Sasaki, Mitsugu Fujita, Xinmei Zhu, Michael T. Lotze, Robert W. Sobol, Hideho Okada	1
19	Treatment of 9L gliosarcoma with IL-4 producing 9L vaccine 1996 ·The FASEB Journal ·Michael Bozik, William H. Chambers, (unknown), Michael T. Lotze	3
20	SURGICAL CONSIDERATIONS IN THE DIAGNOSIS AND MANAGEMENT OF AIDS* 1986 ·PubMed ·Michael T. Lotze	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact